...
首页> 外文期刊>Journal of Molecular Biology >gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: Investigation of its low activity and quinolone hypersensitivity
【24h】

gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: Investigation of its low activity and quinolone hypersensitivity

机译:gyrB-225,一种DNA回旋酶的突变,可弥补拓扑异构酶I的不足:其低活性和喹诺酮类超敏反应的研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The B subunit of DNA gyrase (GyrB) consists of a 43 kDa N-terminal domain, containing the site of ATP binding and hydrolysis, and a 47 kDa C-terminal domain that is thought to play a role in interactions with GyrA and DNA. In cells containing a deletion of topA (the gene encoding DNA topoisomerase I) a compensatory mutation is found in gyrB. This mutation (gyrB-225) results in a two amino acid insertion in the N-terminal domain of GyrB. We found that cells containing this mutation are more sensitive than wild-type cells to quinolone drugs with respect to bacteriostatic and lethal action. We have characterised the mutant GyrB protein in vitro and found it to have reduced DNA supercoiling, relaxation, ATPase, and cleavage activities. The mutant enzyme is up to threefold more sensitive to quinolones than wild-type. The mutation also increases the affinity of GyrB for GyrA and DNA, while the affinity of quinolone for the enzyme-DNA complex is unaffected, We propose that the loss in activity is hue to misfolding of the GyrB-225 protein, providing an example in which misfolding of one protein, DNA gyrase, suppresses a deficiency of another, topoisomerase I. The increased quinolone sensitivity is proposed to be a consequence of an altered conformation of the protein that renders quinolones better able to disrupt, rather than generate, gyrase-drug-DNA complexes. (C) 2001 Academic Press. [References: 44]
机译:DNA促旋酶(GyrB)的B亚基由一个43 kDa的N末端结构域(包含ATP结合和水解位点)和一个47 kDa的C末端结构域(被认为在与GyrA和DNA的相互作用中起作用)组成。在含有topA(编码DNA拓扑异构酶I的基因)缺失的细胞中,在gyrB中发现了代偿性突变。此突变(gyrB-225)导致GyrB N端结构域插入两个氨基酸。我们发现,在抑制细菌和致死作用方面,含有这种突变的细胞比野生型细胞对喹诺酮类药物更敏感。我们已经表征了突变体GyrB蛋白在体外,并发现它具有降低的DNA超螺旋,松弛,ATPase和裂解活性。突变酶对喹诺酮类的敏感性比野生型高三倍。该突变还增加了GyrB对GyrA和DNA的亲和力,而喹诺酮对酶-DNA复合物的亲和力不受影响。我们提出活性的损失归因于GyrB-225蛋白的错误折叠,提供了一个例子一种蛋白质(DNA促旋酶)的错误折叠会抑制另一种拓扑异构酶I的缺失。有人认为,喹诺酮敏感性提高是蛋白质构象改变的结果,这种改变使喹诺酮能够更好地破坏而不是产生促旋酶-药物- DNA复合物。 (C)2001学术出版社。 [参考:44]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号